## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.16 indicates fundamental undervaluation. Quality metrics strong (ROE 62%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($114.43)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 2)

**1. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com | 20251215T160807 | Somewhat-Bullish | Relevance: 100%
- UBS has reaffirmed its Buy rating on DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a 53% upside from its current trading price. The firm cites DaVita's solid financial health and long-term operating income growth expectations of 3-7%, despite a recent earnings per share miss in Q3 2025. DaVita's growth framework includes contributions from U.S. dialysis, Integrated Kidney Care, and international business, with IKC projected to reach breakeven by 2026.

**2. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com Nigeria | 20251215T170754 | Neutral | Relevance: 100%
- UBS has reiterated its Buy rating on DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a potential 53% upside. The investment firm projects DaVita's long-term adjusted operating income growth to be in the 3-7% range, driven by contributions from U.S. dialysis operations, Integrated Kidney Care (IKC), and international business. This outlook comes despite a recent Q3 2025 earnings miss, with the company aiming for IKC segment breakeven by 2026.

**3. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com UK | 20251215T152010 | Somewhat-Bullish | Relevance: 100%
- UBS has re-affirmed its Buy rating for DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a 53% upside from its current trading price. The firm cites DaVitaâ€™s solid financial health and long-term adjusted operating income growth expectations of 3-7%, despite a recent Q3 2025 earnings per share and revenue miss. UBS also noted consistent growth frameworks and anticipated breakeven for DaVita's Integrated Kidney Care segment in 2026.

**4. Is DaVita Stock Underperforming the Dow?**
- Source: Markets Financial Content | 20251215T140500 | Bearish | Relevance: 100%
- DaVita Inc. (DVA), a mid-cap company providing kidney dialysis services, has experienced a significant underperformance compared to the Dow Jones Industrials Average ($DOWI). Its stock has decreased by 32.4% from its 52-week high, dropped 8.9% in the last three months, and declined 21.2% over the past year, while the DOWI has seen gains. Analysts are cautious, rating DVA as a "Hold" with a modest price target premium, particularly after a disappointing Q3 2025 due to higher costs, lower volumes, and a ransomware attack.

**5. Neuberger Berman Group LLC Buys 128,871 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251214T140729 | Somewhat-Bearish | Relevance: 100%
- Neuberger Berman Group LLC significantly increased its stake in DaVita Inc. by 197.2% in Q2, acquiring 128,871 shares, bringing its total to 194,235 shares valued at $27.67 million. Other institutional investors also boosted their positions, resulting in institutional ownership of 90.12%. Despite this, DaVita missed Q3 EPS estimates, offered cautious FY2025 guidance, and holds a "Reduce" consensus analyst rating with a $148 price target.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 11.7% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.16 suggests fair value with growth premium. Forward P/E 9.4x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.6B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.16 |
| Forward P/E | 9.4 |
| Current P/E | 11.2 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.1% to 1.5% (+5.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (0.55), confirming momentum. RSI neutral at 50. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.51% (CS: 48) | Neutral |
| RSI_14 | 49.8 | Neutral |
| MACD Histogram | 0.55 | Bullish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 0.883x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $120.05
- **Stop Loss:** $114.43 (4.7% risk)
- **Target:** $131.29 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 213
- **Position Value:** $25,570.65
- **Portfolio %:** 25.57%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*